ATLANTA, March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. ET on March 13, 2023. A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 59-2417093 (State or other jurisdiction of incorpo ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Artivion (AORT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Artivion is one of 1067 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Ran ...

Shares of Artivion (AORT) have been strong performers lately, with the stock up 15.9% over the past month. The stock hit a new 52-week high of $19.63 in the previous session. Artivion has gained 9.5% since the start of the year compared to the 6% move for the Zacks Medical sector and the 4.4% return for the Zacks Medical - Instruments industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last ...

Group 1: Stock Performance and Price Targets - Artivion (AORT) closed at $18.70, with a 6.3% gain over the past four weeks, and a mean price target of $24.44 indicating a 30.7% upside potential [1] - The average price target ranges from a low of $22 to a high of $25.75, with a standard deviation of $1.66, suggesting a relatively high agreement among analysts [1][4] - The lowest estimate indicates a 17.7% increase, while the most optimistic estimate points to a 37.7% upside [1] Group 2: Analyst Consensus and Earnings Estimates - Analysts show strong agreement in revising AORT's earnings estimates higher, which correlates with potential stock price increases [5] - The Zacks Consensus Estimate for the current year has increased by 2500%, reflecting positive sentiment among analysts [5] - AORT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [6] Group 3: Limitations of Price Targets - Price targets set by analysts can often mislead investors, as empirical research indicates they rarely predict actual stock price movements [3][4] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [3] - While price targets should not be ignored, they should be approached with skepticism and not be the sole basis for investment decisions [4]

Artivion, Inc. (NYSE:AORT) Q4 2023 Earnings Conference Call February 15, 2024 4:30 PM ET Company Participants Laine Morgan - IR, Gilmartin Group Pat Mackin - CEO Lance Berry - CFO Conference Call Participants John McAulay - Stifel Mike Matson - Needham Suraj Kalia - Oppenheimer Jeffrey Cohen - Ladenburg Thalmann Nelson Cox - Lake Street Capital Operator Greetings, and welcome to the Artivion Fourth Quarter and Year-End 2023 Financial Conference Call. At this time, all participants are in a listen-only mode. ...

Artivion (AORT) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 184.62%. A quarter ago, it was expected that this biological medical device maker would post earnings of $0.01 per share when it actually produced earnings of $0.02, delivering a surprise of 100%.Over the last f ...

ARTIVION 3Q 2023 Earnings Presentation November 2, 2023 11 © 2023 Artivion, Inc. FORWARD-LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management’s beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs th ...

Artivion, Inc. (NYSE:AORT) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group Pat Mackin - Chairman, President, and Chief Executive Officer Ashley Lee - Executive Vice President and Chief Financial Officer Conference Call Participants John McAulay - Stifel Shaymus Contorno - Oppenheimer Joseph Stringer - Needham Frank Takkinen - Lake Street Capital Jeffrey Cohen - Ladenburg Thalmann Operator Welcome to the Artivion Third Quarter 2023 Financial Co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission file number: 1-13165 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware ...